We are a clinical stage biopharmaceutical company engaged in the discovery and development of synthetic derivatives of newly discovered endogenous hormones that target misfolded proteins, including alpha-synuclein in Parkinson’s Disease, or PD, amyloid beta and tau in Alzheimer’s Disease, or AD, as well as targeting insulin resistance which is